Lymphocyte response in patients with head and neck cancer: effect of clinical stage and radiotherapy

Arch Otolaryngol. 1976 Oct;102(10):596-600. doi: 10.1001/archotol.1976.00780150064003.

Abstract

Ffty-three patients with head and neck cancer tested before radiation treatment to determine numbers of blood lymphocytes and immunologic responses to mitogens of lymphocytes in whole-blood cultures had mean values that were 19% to 26% less than values for healthy individuals. Thirty patients whose disease was in stages III or IV had values similar to those in 23 patients whose disease was in stages I or II. Values for 45 patients tested at end of radiotherapy decreased to about 50% of pretreatment values; however, patients with advanced lesions experienced greater decreases (to 24% to 50%) than patients with localized lesions (to 71% to 84%). Patients with advanced lesions usually received radiation to larger areas than patients with localized lesions; therefore, the extent of decline in laboratory values was most likely dependent on volume of tissue treated.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Concanavalin A / immunology
  • Head and Neck Neoplasms / immunology*
  • Head and Neck Neoplasms / pathology
  • Head and Neck Neoplasms / radiotherapy
  • Humans
  • Hydroxyurea / therapeutic use
  • Lectins / immunology
  • Leukocyte Count
  • Lymphocyte Activation*
  • Lymphocytes / immunology
  • Radiotherapy Dosage

Substances

  • Lectins
  • Concanavalin A
  • Hydroxyurea